A recent CVS Health/Morning Consult survey of Americans age 18+ found that mental health concerns are continuing to rise among individuals of all backgrounds, especially Black, age 65+, young adult, and LGBTQIA+ respondents.
Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”
Join this webinar session for case study examples that demonstrate how innovative pharma marketers are utilizing social networks as a force for good to cultivate lasting consumer relationships and improve patient outcomes. Learn what’s working – and what pitfalls to avoid – in today’s rapidly evolving digital landscape.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, and UpScriptHealth, a leading telehealth and virtual prescribing platform serving life sciences companies, announced a strategic partnership to create a direct-to-patient platform that will transform the patient experience to help accelerate access to therapies worldwide.
Global health innovation company Real Chemistry announced the acquisition of conversationHEALTH, a conversational artificial intelligence (AI) platform for the health care and life sciences industry.
A new research study by Klick Health and ThinkNow reveals significant cultural differences in the way Hispanics deal with their health – reinforcing the need for cross-cultural marketing programs by healthcare companies targeting this growing population segment.
Pear Therapeutics, Inc. has announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options.
The Digital Medicine Society (DiMe), in partnership with Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op, announced the public launch of the 3Ps of Digital Endpoint Value (3Ps), a toolkit of resources created to facilitate the inclusion of digital endpoints as evidence for payers in reimbursement decisions for new drugs.
Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors.
Fishawack Health (FH) – a leading commercialization partner for biopharmaceutical, medical technology, and wellness companies – welcomed the US-based health economics and outcomes research consultancy Policy Analysis Inc. (PAI) as part of the company’s expanding Value, Evidence, and Access (VEA) capability.